Acrivon Therapeutics, Inc. Common Stock
$1.85
Market Cap
$72.85M
Shares Outstanding
42.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 15, 2022
Round Lot
100
Locale
US
Day Open
$1.71
Day High
$1.90
Day Low
$1.69
Volume
478.2K
VWAP
$1.81
Prev Close
$1.70
Transactions
--
Acc. Volume
--
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Acrivon Therapeutics, Inc. Common Stock (ACRV) closed the 2026-09-18 session at $1.85, up 8.82% versus the previous close (+0.15). The stock opened at $1.71 and traded between $1.69 and $1.90 during that session. Session trading volume was 478K shares. The volume-weighted average price (VWAP) is $1.81.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Acrivon Therapeutics, Inc. Common Stock has a market capitalization of $72.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ACRV is listed on the XNAS exchange. The company employs approximately 76 people. Acrivon Therapeutics, Inc. Common Stock is headquartered in WATERTOWN, MA. The recorded listing date is 2022-11-15.
On this page you can find market ACRV stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.